新型抗结核药物贝达喹啉的作用及其研究进展  

Mechanism and research progress of bedaquiline:a novel anti-tuberculosis drug

作　　者：应苗法[1] 朱剑萍[1] 马珂[1] 俞振伟[1] 韩钢[1] 

机构地区：[1]浙江大学医学院附属邵逸夫医院,浙江杭州310016

出　　处：《中国新药与临床杂志》2014年第5期325-329,共5页Chinese Journal of New Drugs and Clinical Remedies

基　　金：浙江省医药卫生一般研究计划(2012KYB110)

摘　　要：贝达喹啉是近年来第一个具有全新抗结核杆菌机制的药物,是治疗结核杆菌感染的有力武器。贝达喹啉通过特异性地抑制结核杆菌的ATP合酶发挥作用,对耐药和非耐药结核杆菌均有作用。动物实验和临床试验均证实了贝达喹啉对结核的有效性和安全性。本文在检索国内外文献的基础上,对贝达喹啉的作用机制、体外抗菌活性、临床前研究和临床研究等方面的研究进展进行了综述。Bedaquiline is the first drug in the recent years with novel mechanism of action, and it may play an important role in the therapy of tuberculosis. Bedaquiline can inhibit the ATP synthase specifically and exhibit inhabitation effect on drug- resistant and sensitive Mycobacterium tuberculosis. The effectiveness and safety of bedaquiline on tuberculosis was confirmed by animal models and clinical trails. The mechanism of action, in vitro anti- bacterial effect, preclinical and clinical research and other research progresses of bedaquiline were reviewed in this article based on research literatures.

关 键 词：贝达喹啉 结核 抗结核药 ATP合成酶复合物 

分 类 号：R978.3[医药卫生—药品]